AstraZeneca received FDA approval for Faslodex (fulvestrant), a treatment for hormone receptor positive metastatic breast cancer in postmenopausal women whose cancer progresses despite treatment with anti-estrogen drugs, such as tamoxifen. The market for breast cancer drugs in the United States, according to AZ, is valued at more than $1 billion.
COPYRIGHT 2002 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2002 Gale Group